欢迎访问ProbeChem中文网站,英文网站请访问www.probechem.com

首页-小分子抑制剂&激动剂-Nuclear Receptor/Transcription Factor-ROR-RORγt agonist 8-074
RORγt agonist 8-074

Chemical Structure : RORγt agonist 8-074

CAS No.: 2211060-52-3

RORγt agonist 8-074

货号: PC-49473Not For Human Use, Lab Use Only.

RORγt agonist 8-074 is a potent, selective RORγt agonist with Kd of 497 nM, shows potent RORγt agonist activity in the Gal4 reporter gene assay with EC50 of 118.7 nM, and EC50 of 19.95 nM in FRET assays.

规格 价格 库存 数量
50 mg Get quote
100 mg Get quote
250 mg Get quote

大包装,大折扣!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

纯度 & COA & 质检文件 纯度: >98% (HPLC) Select Batch:

    生物&药学活性

    RORγt agonist 8-074 is a potent, selective RORγt agonist with Kd of 497 nM, shows potent RORγt agonist activity in the Gal4 reporter gene assay with EC50 of 118.7 nM, and EC50 of 19.95 nM in FRET assays.
    RORγt agonist 8-074 displayed high selectivity versus the other two ROR members.
    RORγt agonist 8-074 demonstrates stimulating the mouse Tc17 cells with EC50 at 11.21 nM.
    RORγt agonist 8-074 demonstrated potent and selective binding to the RORγt protein as well as potent in vitro activity compared with LYC-55716.
    RORγt agonist 8-074 promoted the secretion of IL-17A by Th17 cells with EC50 of 22.78 nM.
    RORγt agonist 8-074 (160 nM) significantly increased the percentage of CD4+ T and CD8+ T cells that express IL-17A (from 12.1% to 24.0% in CD4+ T and 22.9% to 50.4% in CD8+ T cells).
    RORγt agonist 8-074 (50 mg/kg, i.p. injection, QD over two weeks) showed robust antitumor efficacy in syngeneic tumor models, and 8-074 improved the efficacy of anti‑PD‑1 therapy in murine lung cancer models.

    物理化学性质&存储条件

    分子量 528.590
    分子式 C28H27F3N2O3S
    外观性状 Solid
    CAS No.
    储存条件
    固体粉末
    -20°C 12 个月; 4°C 6 个月
    配置液
    -80°C 6 个月; -20°C 6 个月
    Shipping
    Solubility

    10 mM in DMSO

    Chemical Name/SMILES

    N-(3'-cyano-4'-isobutyl-2-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide

    参考文献

    1. Li Xia, et al. J Exp Clin Cancer Res. 2022 Apr 23;41(1):155.

    备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

    联系我们 sales@probechem.com

    Bulk Inquiry

    * Indicates a Required FieldYour information is safe with us.

    • *Product name:
    • *Applicant name:
    • *Email address:
    • *Organization name:
    • *Requested quantity:
    • *Country:
    • *Additional Information:

    询单

    • *产品名称:
    • *姓名:
    • *邮箱:
    • *公司名称:
    • *询单数量:
    • *国籍:
    • 询单信息: